New treatment for advanced endometrial cancer after prior therapy
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new immunotherapy drug (QL1706) for people with advanced endometrial cancer whose previous immunotherapy stopped working. It aims to see if this different approach can help when standard treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have advanced or recurrent endometrial cancer that has spread or come back.
- You have tried and failed 2 or fewer prior cancer treatments (hormone therapy does not count).
- Your previous immunotherapy (PD-1 or PD-L1 blocker) worked for at least 6 months before it stopped working.
- You have not had a type of immunotherapy called PD-1/CTLA-4 dual-target therapy before.
- You do not have active autoimmune disease or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two investigational drugs—anlotinib (a capsule that blocks blood supply to tumors) and TQB2450 (an immunotherapy that helps your immune system attack cancer cells)—for people with recurrent or metastatic endometrial cancer that has not responded to previous platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow their growth.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy for women with advanced or recurrent endometrial cancer that hasn't been treated yet. It may help shrink or control the cancer.
This trial tests a new combination of an immunotherapy drug (QL1706) plus two chemotherapy drugs (AG regimen) as a first treatment for advanced pancreatic cancer. It aims to see if this mix works better than standard care.
This trial tests if adding a new immunotherapy drug (QL1706) to standard chemotherapy works better than chemotherapy alone for triple-negative breast cancer that has returned or spread. This is for people who have already tried 1 or 2 other treatments.
This trial tests a new drug called QL1706 for people with cervical cancer that has spread and no longer responds to PD-1/PD-L1 therapy. It may offer a new treatment option if you have tried this type of immunotherapy before.
This trial tests adding a new immunotherapy drug (QL1706) to standard chemotherapy plus bevacizumab for people with colorectal cancer that has spread and hasn't been treated yet. It aims to see if the combination works better than standard treatment alone.
Hear when a new Endometrial Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.